Literature DB >> 11201865

Steroids in leprosy type 1 (reversal) reactions: mechanisms of action and effectiveness.

D N Lockwood1.   

Abstract

Steroids are widely used for the treatment of leprosy reactions. The effectiveness of steroid treatment is variable, with only 60% of patients regaining nerve function. Sequential skin biopsy specimens, obtained from 15 patients with type 1 (reversal) reactions, have been studied to document the cytokine profile and cellularity of the lesions. All of the patients were placed on a standard course of steroids after the first biopsy. Subsequent biopsies were performed seven, 28 and 180 days later. The specimens were stained for interferon-gamma (IFN gamma), interleukin-12 (IL-12) and inducible nitric oxide synthase (iNOS). After the first biopsy, all patients were placed on a standard reducing course of steroids beginning at 30 mg daily. By day 7, treatment with prednisolone showed little effect on the cellularity and cytokine profiles. However, by day 28, significant decreases of IFN-gamma, IL-12 and iNOS were found for most patients. Some patients maintained cytokine production at day 28 and even at day 180. These data illustrate the strong Th1 profile of type 1 reactional lesions, the relatively slow response to therapy, and the continuing activity after treatment with steroids for 180 days. The variation of individual responses emphasizes their importance. Additional prospective studies will be required to determine whether patients with high intra-lesional levels of cytokine are at risk of recurrent reactions. The need for studies both of different glucocorticoids and of other non-steroidal immunosuppressants for the treatment of reactions is discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11201865     DOI: 10.5935/0305-7518.20000080

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  8 in total

Review 1.  Leprosy elimination-a virtual phenomenon or a reality?

Authors:  Diana N J Lockwood
Journal:  BMJ       Date:  2002-06-22

Review 2.  Mycobacterium leprae-host-cell interactions and genetic determinants in leprosy: an overview.

Authors:  Roberta Olmo Pinheiro; Jorgenilce de Souza Salles; Euzenir Nunes Sarno; Elizabeth Pereira Sampaio
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

3.  Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1).

Authors:  W Cairns S Smith; Alison M Anderson; Stephen G Withington; Wim H van Brakel; Richard P Croft; Peter G Nicholls; Jan Hendrik Richardus
Journal:  BMJ       Date:  2004-05-24

4.  Leprosy therapy, past and present: can we hope to eliminate it?

Authors:  P V S Prasad; P K Kaviarasan
Journal:  Indian J Dermatol       Date:  2010-10       Impact factor: 1.494

5.  Serological responses to prednisolone treatment in leprosy reactions: study of TNF-α, antibodies to phenolic glycolipid-1, lipoarabinomanan, ceramide and S100-B.

Authors:  Renuka Raju; Sujai Suneetha; Rupendra S Jadhav; MeherVani Chaduvula; Sara Atkinson; Suman Jain; Leo H Visser; Loretta Das; Ravindra Panhalkar; Vidyagouri Shinde; Parphananda P Reddy; Pramila Barkataki; Diana Nj Lockwood; Wim H Van Brakel; Lavanya M Suneetha
Journal:  Lipids Health Dis       Date:  2014-07-28       Impact factor: 3.876

6.  A Randomized Controlled Double Blind Trial of Ciclosporin versus Prednisolone in the Management of Leprosy Patients with New Type 1 Reaction, in Ethiopia.

Authors:  Saba M Lambert; Digafe T Alembo; Shimelis D Nigusse; Lawrence K Yamuah; Stephen L Walker; Diana N J Lockwood
Journal:  PLoS Negl Trop Dis       Date:  2016-04-05

Review 7.  Leprosy in Denmark 1980-2010: a review of 15 cases.

Authors:  Huma Aftab; Susanne D Nielsen; Ib C Bygbjerg
Journal:  BMC Res Notes       Date:  2016-01-05

8.  Effectiveness of 32 versus 20 weeks of prednisolone in leprosy patients with recent nerve function impairment: A randomized controlled trial.

Authors:  Inge Wagenaar; Erik Post; Wim Brandsma; Bob Bowers; Khorshed Alam; Vanaja Shetty; Vivek Pai; Sajid Husain; Cita Rosita Sigit Prakoeswa; Linda Astari; Deanna Hagge; Mahesh Shah; Kapil Neupane; Krishna Bahadur Tamang; Peter Nicholls; Jan Hendrik Richardus
Journal:  PLoS Negl Trop Dis       Date:  2017-10-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.